211 related articles for article (PubMed ID: 29342499)
1. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Deakin CT; Campanilho-Marques R; Simou S; Moraitis E; Wedderburn LR; Pullenayegum E; Pilkington CA;
Arthritis Rheumatol; 2018 May; 70(5):785-793. PubMed ID: 29342499
[TBL] [Abstract][Full Text] [Related]
2. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
[TBL] [Abstract][Full Text] [Related]
3. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.
Villa-Forte A; Clark TM; Gomes M; Carey J; Mascha E; Karafa MT; Roberson G; Langford CA; Hoffman GS
Medicine (Baltimore); 2007 Sep; 86(5):269-277. PubMed ID: 17873756
[TBL] [Abstract][Full Text] [Related]
4. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.
Bae S; Charles-Schoeman C
Clin Rheumatol; 2018 Aug; 37(8):2113-2123. PubMed ID: 29971584
[TBL] [Abstract][Full Text] [Related]
5. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment.
Kim S; El-Hallak M; Dedeoglu F; Zurakowski D; Fuhlbrigge RC; Sundel RP
Arthritis Rheum; 2009 Jun; 60(6):1825-1830. PubMed ID: 19479872
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.
Campanilho-Marques R; Deakin CT; Simou S; Papadopoulou C; Wedderburn LR; Pilkington CA;
Arthritis Res Ther; 2020 Apr; 22(1):79. PubMed ID: 32293539
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.
Tsuji H; Nakashima R; Hosono Y; Imura Y; Yagita M; Yoshifuji H; Hirata S; Nojima T; Sugiyama E; Hatta K; Taguchi Y; Katayama M; Tanizawa K; Handa T; Uozumi R; Akizuki S; Murakami K; Hashimoto M; Tanaka M; Ohmura K; Mimori T
Arthritis Rheumatol; 2020 Mar; 72(3):488-498. PubMed ID: 31524333
[TBL] [Abstract][Full Text] [Related]
8. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
Deakin CT; Yasin SA; Simou S; Arnold KA; Tansley SL; Betteridge ZE; McHugh NJ; Varsani H; Holton JL; Jacques TS; Pilkington CA; Nistala K; Wedderburn LR;
Arthritis Rheumatol; 2016 Nov; 68(11):2806-2816. PubMed ID: 27214289
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.
Suzuki Y; Hayakawa H; Miwa S; Shirai M; Fujii M; Gemma H; Suda T; Chida K
Lung; 2009; 187(3):201-6. PubMed ID: 19387736
[TBL] [Abstract][Full Text] [Related]
11. Update on therapy for refractory dermatomyositis and polymyositis.
Villalba L; Adams EM
Curr Opin Rheumatol; 1996 Nov; 8(6):544-51. PubMed ID: 9018458
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features of patients with juvenile and adult dermatomyositis].
Szalmás O; Nagy-Vince M; Dankó K; Farkas F
Orv Hetil; 2015 Sep; 156(37):1491-6. PubMed ID: 26552025
[TBL] [Abstract][Full Text] [Related]
13. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Mira-Avendano IC; Parambil JG; Yadav R; Arrossi V; Xu M; Chapman JT; Culver DA
Respir Med; 2013 Jun; 107(6):890-6. PubMed ID: 23517887
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
[TBL] [Abstract][Full Text] [Related]
15. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV
Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
Faurschou M; Westman K; Rasmussen N; de Groot K; Flossmann O; Höglund P; Jayne DR;
Arthritis Rheum; 2012 Oct; 64(10):3472-7. PubMed ID: 22614882
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.
Al-Mayouf S; Al-Mazyed A; Bahabri S
Clin Rheumatol; 2000; 19(2):138-41. PubMed ID: 10791626
[TBL] [Abstract][Full Text] [Related]
18. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
[TBL] [Abstract][Full Text] [Related]
19. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
